Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Palazestrant - Olema Pharmaceuticals

Next Previous
Drug Profile

Palazestrant - Olema Pharmaceuticals

Alternative Names: OP-1250

Latest Information Update: 29 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Olema Pharmaceuticals
  • Developer Novartis; Olema Pharmaceuticals; Pfizer
  • Class 3-ring heterocyclic compounds; Alkanes; Antineoplastics; Azetidines; Fluorinated hydrocarbons; Indoles; Phenyl ethers; Pyridines; Small molecules
  • Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HER2 negative breast cancer
  • Preclinical HER2 positive breast cancer
  • Research Endometrial cancer; Gynaecological cancer

Most Recent Events

  • 16 Mar 2026 Phase-I/II clinical trials in HER2-negative-breast-cancer (Metastatic disease, Combination therapy) (PO) prior to March 2026
  • 16 Mar 2026 Olema Pharmaceuticals announces intention to submit the regulatory application for the approval of palazestrant for HER2- negative breast cancer and anticipates approval in late 2027
  • 16 Mar 2026 Olema Pharmaceuticals plans to launch palazestrant for HER2- negative Breast cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top